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OBJECTIVES: This paper discusses the influence of a para-areolar incision in the upper outer quadrant of the breast
on the location of the sentinel lymph node in a canine model.
METHODS: The sentinel lymph node was marked with technetium-99, which was injected into the subareolar skin of
the cranial breast. After the marker had migrated to the axilla, an arcuate para-areolar incision was performed 2 cm
from the nipple in the upper outer quadrant. Patent blue dye was then injected above the upper border of the
incision. At the marked site, an axillary incision was made, and the sentinel lymph node was identified by gamma
probe and/or by direct visualization of the dye. The agreement between the two injection sites and the two sentinel
lymph node identification methods was determined. Our sample group consisted of 40 cranial breasts of 23 adult
females of the species Canis familiaris. The data were analyzed by using the McNemar test and by determining the
kappa agreement coefficient.
RESULT: Our findings showed that in 95% of the breasts, the sentinel lymph node was identified by the injection of
technetium-99 m into the subareolar region, and in 82% of the cases, the sentinel lymph node was identified by the
injection of patent blue dye above the upper border of the incision. The methods agreed 82% of the time.
CONCLUSIONS: Previous para-areolar incisions in the upper outer quadrant did not interfere significantly with the
biopsy when the dye was injected above the upper border of the incision.
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INTRODUCTION
In 1977, Cabanas1 reported the identification of nodal
drainage pathways and a sentinel node from penile cancer.
Sentinel lymph node (SLN) biopsy, introduced in the mid-
1990s, has revolutionized the management of breast cancer
patients.2,3 The use of this method has significantly reduced
the need for extensive axillary dissection to establish a
reliable prognosis in breast cancer treatment.
Using isosulfan blue dye, Morton et al.4 demonstrated the
accuracy of sentinel node biopsy for nodal staging and the
management of patients with primary cutaneous melanoma.
The authors determined that if the sentinel node tumor was
not yet committed to the tumor state, then the other nodes
in the lymphatic network would also be healthy. They
reported a 1% rate of false negatives, opening prospects for
research throughout the world.5-7
In 1993, Alex et al.8 injected technetium and introduced
the technique of gamma probe-guided surgery to identify
the sentinel node. In the same year, Krag et al.9 published a
study on the sentinel node using technetium-99 (Tc99) with
probes used for the detection of gamma rays in breast
cancer. They concluded that the radiolocation and selective
resection of the sentinel lymph node was feasible and could
be used to determine the status of the axillary lymph node.
The initial techniques of SLN injection in breast cancer
were intended to aid in the location of the drainage route of
tumor metastasis; the dye or radiopharmaceuticals were
injected into the peritumoral region. Following the increased
understanding of the lymphatic drainage of the breast,
superficial injection techniques have been implemented.10,11
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Based on this knowledge, most centers have adopted the
following superficial injection techniques: subdermal, intra-
dermal, subareolar, or periareolar. These techniques have
been chosen because they are technically easy, highly
reproducible and provide a higher rate of identification and
lower false-negative rates than does peritumoral injection.12
In daily practice, the surgeon often uses the arcuate-
areolar incision for access to nodes or foci of micro-
calcifications in the upper breast quadrant. In cases of
previously diagnosed, biopsied cancer patients where the
histopathological diagnosis pointed to additional surgical
procedures, some authors claim that the SLN identification
should be performed by injecting markers immediately
above the incision.13 In this case, it is questionable if the
node identified by this technique is the same as the one
identified with the marker injected into the subpapilar space
following a skin incision. Therefore, this study aimed to
evaluate, in an experimental model, whether para-areolar
incisions in the upper outer quadrant of the paired cranial
thoracic breasts of bitches interfere with the identification of
the SLN.
MATERIALS AND METHODS
All studies were conducted according to the rules of the
Brazilian College of Animal Experimentation (COBEA).
The use of the radioactive tracer Tc99 was approved by the
National Nuclear Energy Commission (CNEN) and the
Institute for Energy and Nuclear Research (IPEN). Approval
for the experimental use of laboratory animals was obtained
from the Committee of Ethics in Animal Research of the
Federal University of Ceara´.
Sample group - The sample group consisted of 40 breasts
obtained from 23 healthy bitches of undefined breeds of the
species Canis familiaris, housed in the Zoonosis Control
Center Kennel of the City of Fortaleza.
Inclusion criteria - Inclusion in the study required clinically
healthy bitches, who showed well-defined cranial thoracic
breasts and nipples.
Exclusion criteria – The animals weren’t included if they
were under six months old, weighed either less than 5 kg or
more than 15 kg and presented with cranial thoracic breast
atrophy, previous surgery and/or scars. As a radiotracer,
we used 0.2 mL Tc99 phytate (Conselho Nacional de
Energia Nuclear – CNEN, Brazil).
Surgical procedure
After immobilization on the operating table with the legs
abducted, the animals were anesthetized subcutaneously
with 0.05 mg/kg atropine (CentralvetH, Brazil) followed by
15 mg/kg ketamine hydrochloride (SyntecH, Brazil) and
1.5 mg/kg xylazine hydrochloride (SyntecH, Brazil) intra-
muscularly. The level of anesthesia was monitored con-
tinuously by clinical parameters, such as movements of the
nostrils and other muscle groups and respiratory and
cardiac rates. Additional anesthesia was provided as
required. Venipuncture in an upper paw with a 9- or 21-
gauge ‘‘scalp’’ needle was performed for the administration
of 0.9% saline to secure adequate venous access. The
surgical areas of the breast and axilla were shaved to
remove excess hair. Subsequently, 0.2 ml Tc99 phytate was
injected intradermally using a fine-gauge insulin needle in
the subareolar region of both cranial thoracic breasts
(Figure 1). Two-minute bidigital massage was provided to
promote the migration and transport of the radiocolloid
particles to the lymphatic system.
Five minutes after the Tc-99 subareolar injection, axillary
mapping was performed using a gamma probe that was
covered with a surgical glove (Figure 2) to identify the
location of the point of maximum uptake of the gamma
radiation in the axilla, which represents the projection of the
sentinel node.
The upper breast quadrants were outlined with a der-
mographic pen, using the nipple as the center point. The
quadrants delineated segments with axes that were 2 cm
distant from the center of the nipple and formed a 90-degree
angle at the junction point. The arcuate incision position and
extent were determined by linking the two distal ends of the
axes. Therefore, the incisions were placed between 12 – 15 h
(left breast) and 9 – 12 h (right breast), 2 cm from the nipple.
After incision and hemostasis by compression of the
wound, 0.5 ml blue dye (bleu patente´ V Guerbet 2.5%) was
injected just above the midpoint of the arcuate top edge of
Figure 1 - Intradermal injection of 99mTc into the subareolar
region of cranial thoracic breasts using a fine-gauge insulin
needle.
Figure 2 - Performing axillary mapping using a gamma probe to
identify the location of the projection of the sentinel node in the
axilla.
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the incision in the subdermal region (Figure 3). Local
compression and gentle massage at the site of injection were
applied to prevent the contrast from spreading farther and
to allow it to be transported by the lymphatic network of the
area to the sentinel node.
After five minutes, the axillary point of the highest
radiation uptake was identified with the gamma probe
NuclearLab-DGC-8. A 3-cm-long axillary incision was made
at this point, followed by a careful dissection that was
guided by the visualization of a bluish afferent lymphatic
system that pointed to the SLN(s). When the afferent
lymphatic vessels were difficult to identify, the location of
the SLN with the gamma probe was necessary to guide the
incision site.
A significant radioisotope uptake should be at least five-
fold higher than the background radioactivity in the armpit.
The background radioactivity represents the count that was
obtained in four axillary equidistant points from the point of
injection or the location of the sentinel node.
Upon complete exposure of the identified SLN, the
radiocolloid uptake was measured in vivo and ex vivo after
the removal of the SLN (Figures 4-5). The values obtained
were registered for subsequent analysis. The position of the
sentinel lymph node, as identified by the blue dye, was
compared with the location identified by the gamma probe
to check whether there was agreement between the two
methods. Radiation was also measured in the surgical bed
to identify any remaining hot lymph nodes. If positive, the
lymph node was removed, and its radiation and dye uptake
characteristics were recorded. The area ratio of the greatest
uptake/background radiation of the surgical bed should be
greater than or equal to ten. Verification of the radioactivity
of the SLN after removal from the surgical field (ex-vivo
counting) and comparison with the radioactivity from the
surgical bed confirmed that the SLN was actually removed
and that there was no other source of radiation that could
justify the continuation of a search for another node.
We recorded all radiation rates at the injection site before
the incision was made in the armpit, the sentinel lymph
node radioactivity in vivo and ex vivo and the radioactivity
from the central bed where the sentinel bed was located.
The parameter used was the background radioactivity
(radiation control). The tabulated data quantified the
intersection between the two markings and the correlation
between the methods.
Figure 3 - Injection of blue dye (bleu patente´ V Guerbet 2.5%)
just above the midpoint of the arcuate top edge of the incision
in the subdermal region.
Figure 4 - Complete exposure of the identified SLN and
measurement of the radiocolloid uptake in vivo before the
removal of the SLN.
Figure 5 -Measurement the radiocolloid uptake ex vivo after the
removal of the SLN.
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The animals were sacrificed after the experiment with the
rapid intravenous injection of 10% potassium chloride,
stored in a suitable plastic bag, placed in refrigeration for at
least two hours, and subsequently sent to the Zoonosis
Control Center Kennel.
Statistical methods
The Graphpad software (http://www.graphpad.com/
quickcalcs/index.cfm) was used for computation and statis-
tical analysis. The data were evaluated by a McNemar test
and the kappa coefficient of concordance. P-values were
determined using Fisher’s exact test. A p-value ,0.05 was
considered to be statistically significant.
RESULTS
From a sample group of 23 bitches (46 breasts), only 40
fulfilled the inclusion/exclusion criteria; 95% of the breasts
studied had an SLN that was identified within the axillary
site by using the gamma probe after an injection of Tc99
phytate into the subareolar region (Table 1). After the
injection of patent blue into the dermis of the upper edge of
the arcuate incision in the upper quadrant of the left breast,
82% (33/40) of the isolated lymph nodes were stained
(Table 2). In the cases studied, there was agreement among
the methods evaluated in 82% (28/43) of cases (Table 3).
Table 4 shows the results that were obtained using Tc99
and patent blue dye (sentinel nodes from the left and right
cranial thoracic bitch breasts). The McNemar test resulted in
p= 0.1306 (IC: 95%). The kappa coefficient of concordance
when comparing Tc99 isolated with a combination of Tc99
and patent blue in a sentinel node assay was 0.157 (82%
observed agreements) (Table 5). The kappa coefficient of
concordance when comparing the single use of patent blue
dye with a combination of Tc99 and patent blue was 0.827
(95% observed agreements) (Table 6).
DISCUSSION
Sentinel node biopsy has evolved with the publication of
the many studies since Cabanas’ original paper in 1977.1
Morton et al.4 identified the SLN in cases of melanoma using
dye, while Krag et al.9 used radiopharmaceuticals and a
gamma detector during surgery and identified the SLN in
82% of cases with a 100% accuracy rate. Using the blue dye,
Giuliano et al.14 obtained rates of 66% for node identification
and 96% for accuracy. Albertini et al.3 used the combination
of dye+Tc99, attaining positive SLN identification 92% of the
time with 100% accuracy. For the past 20 years, SLN biopsy,
which is considered to be a minimally invasive procedure,
has replaced axillary dissection with high accuracy (97 to
99%) in predicting the axillary lymph node status.
Since then, the SLN biopsy has become a standard tool for
addressing the axilla in early breast cancer in many medical
centers worldwide.12-16 The release of the SLN biopsy
method and increased knowledge of breast anatomy have
resulted in many questions about the technical peculiarities
of the method, the best site of injection, the best method, the
best contrast and radiotracers, injection techniques, combi-
nations of methods, the learning curve, tumor character-
istics, and the morbidity associated with the method. In
short, many variables are still under evaluation.
One of the important points that is being discussed
concerns the role that surgery and previous breast biopsies
play in identifying the SLN. Many authors exclude from
their studies patients who were previously diagnosed by
incisional biopsy or by formal excisional resections based on
the assumption that these procedures could interfere in the
identification of the SLN, increase the rates of false
negatives and derail the method.3,17-25 More recently, some
researchers have suggested that previous excisional biopsies
are no impediment to identifying the SLN.26,27 In 2005, the
American Society of Clinical Oncology released some
information based on current data with limited levels of
evidence, suggesting that SLN biopsy was not contra-
indicated in patients with previous diagnoses and excisional
biopsies of the breast.12
Because of the importance of this topic, our study aimed
to assess the influence of the para-areolar incision in the
upper quadrant of the breasts of bitches, considering that
this incision is a common practice of breast clinics when
they are faced with patients with previous surgeries or
biopsies. In these circumstances, the contrast has been
injected into the edges and into the region overlying the scar
without a previous SLN biopsy. The initial use of subareolar
Table 1 - Kappa coefficient of concordance when
comparing isolated patent blue dye with a combination
of Tc99 and patent blue dye in SLN identification.
Tc99 + Patent Blue Dye
Patent Blue Dye Yes No Total
Yes 32 1 33
No 1 6 7
Total 33 7 40
Tc99: technetium99 SLN: Sentinel lymph node
Kappa=0.827/Observed agreements: 95%
Table 2 - Identification of the SLN in the bitch axilla using
the sub-areolar injection of Tc99 into that region of the
right and left breasts.
N %
SLN identification Positive 38 95%
Negative 2 5%
Tc99: technetium99 SLN: Sentinel lymph node
Table 3 - Identification of the SLN in the bitch axilla using
blue dye injection into the dermal region of the upper
edge of the arcuate incision in the left superior quadrant
of the right and left breasts.
N %
SLN identification Positive 32 82%
Negative 7 18%
SLN: Sentinel lymph node
Table 4 - Comparison of the intersection of the methods
discussed in this research to identify the SLN in the axilla
(right and left breasts).
N %
SLN identification Positive 33 82%
Negative 7 18%
SLN: Sentinel lymph node
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Tc99 injection, with identification of the local projection of
the SNL in the armpit after five minutes and the subsequent
use of patent blue dye injected into the upper edge of the
incision, as a method capable of identifying the SLN was
purposely performed in that order because the distance
between the areola and the axilla in the bitch is relatively
small.
It is known that the greater the distance between the
injection of the radio tracer and the uptake area of the
radioactive material by the SLN, the better the lymph node
identification by radio-guided surgery because interference
is avoided between the markings of the injection site and the
uptake site. This phenomenon was observed in this study
because the SLN was identified in 95% of cases (38/40) with
a sub-areolar Tc99 injection. Based on the anatomical-
physiological similarity of the drainages of the human and
bitch breast, we identified the sentinel node by injecting
Tc99 into the subareolar region, and then, after identifying
the presence of radiation in the projection in the axillary
SLN, we performed the para-areolar incision for the left
breast along with the injection of patent blue dye in the
upper edge of the incision. The experiment demonstrated an
SLN identification rate with blue dye and Tc99 of 95% (32/
33) (Table 5-6).
In 33 of the 40 cases, there was agreement (82%) between
the two methods of the SLN identification, i.e., between the
percentage of lymph nodes that captured the Tc99 radio-
isotope and were stained with patent blue or that did not
capture the Tc99 radioisotope and were not stained with
the blue dye. The lymph nodes were not identified in 5% of
breasts with the Tc99 subareolar injection method and in
17.5% using blue dye on the edge of the para-areolar
incision. These findings indicate that the injection of
contrast at the upper edge of the incision, involving the
entire left upper quadrant of the bitch breast, presents a
greater failure rate in identifying the SLN compared to
injection of Tc99 into the breast. This fact can be explained
by injury to the lymphatic drainage pathways that was
caused by the para-areolar incision. The incision was
placed between the subareolar plexus and the lymphatic
system that drains the upper left quadrant of the breast, in
particular the section of the main collecting duct, so as not
to allow part of the lymph nodes to capture the blue patent
dye, as was shown in this model. In our study, due to the
injection of the contrast in the upper edge of the incision, a
positive SLN identification in 82% of cases (32/40) was
obtained.
These results corroborate some of the findings that the
most recent publications have emphasized; namely, there
has been an emphasis on the recommendation of, not a
contraindication to, SLN biopsy in patients with a
previous excisional biopsy because a significant percen-
tage of those patients may benefit from this method.26,27
The hypothesis that the breast skin and underlying
parenchyma drain into the same lymph nodes at the base
of the axilla is based upon their common embryological
origin28,29, justifying the injection of the tracer into the
skin above the incision. Our experimental results reinforce
this hypothesis.
CONCLUSION
In this study, 95% (38/40) of all lymph nodes captured
82% (33/40) of the Tc99 radioisotope and were stained with
the blue dye. With one exception, all nodes were labeled
as sentinel nodes (95%). In 82% of the cases (33/40),
concordance between the methods was verified (Table 5).
These findings may explain why many researchers initially
exclude patients with previous breast biopsies from their
studies because there is a decrease in the rate of identifica-
tion of the SLN in cases where the lymphatic network of the
upper quadrant of the left breast has been damaged by
previous surgery. One fact that must be considered is that
the canine experimental model we created does not evaluate
time interference in the mapping of the sentinel node.
This study shows that lymph nodes found from injection
at the upper edge of a recent incision correspond to the
sentinel node in bitch breasts in 95% of cases (32/33). The
rates of identification of the SLN by the subareolar injection
of Tc99 and the injection of patent blue in the para-areolar
incision were 95% (38/40) and 82% (32/40), respectively. A
previous para-areolar incision in the upper outer breast
quadrants of cranial thoracic bitch breasts does not interfere
significantly in the identification of the sentinel lymph node
when the dye is injected into the upper edge of a recent
incision.
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